Liao, W., Shi, M., Rong, X., Zheng, S., Li, S., Peng, W., Wang, X., Yuan, X., Zeng, W., Wang, C., Deng, Q., Zhang, F., Luo, H., Wang, X. (2026). Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e15539